阿基仑赛与化学免疫治疗在≥2线治疗后复发或难治性大B细胞淋巴瘤老年和/或ECOG体能状态差患者中的获益比较
比较阿基仑赛(axi-cel)与化学免疫治疗(CIT)在≥65岁或ECOG PS=2的复发/难治性大B细胞淋巴瘤患者中的真实世界效果。axi-cel组1146例来自国际血液与骨髓移植研究中心前瞻性观察研究,CIT组469例来自SCHOLAR-1回顾性研究。倾向评分匹配后,axi-cel组12个月总生存率62% vs CIT组28%(HR 0.30,95%CI 0.24-0.37),客观缓解率76% vs 28%。
要点
- axi-cel组12个月总生存率62% vs CIT组28%(HR 0.30,95%CI 0.24-0.37)。
- axi-cel组客观缓解率76%(完全缓解率58%)vs CIT组28%(完全缓解率16%)。
- ≥65岁患者中axi-cel较CIT客观缓解率差异57%(完全缓解率差异55%)。
核心结论
- 研究结果进一步支持在≥65岁及ECOG PS=2的复发/难治性大B细胞淋巴瘤患者中更广泛地使用阿基仑赛。
研究设计与样本
- 非随机比较研究:axi-cel组1146例来自国际血液与骨髓移植研究中心前瞻性观察研究,为≥2线治疗后复发/难治性大B细胞淋巴瘤接受商业axi-cel治疗的患者。
- CIT组469例来自SCHOLAR-1国际多队列回顾性研究,为≥2线治疗后复发/难治性大B细胞淋巴瘤接受化学免疫治疗的患者。
- 采用倾向评分匹配进行分析。
主要发现
- 倾向评分匹配后,axi-cel组中位随访24个月、CIT组中位随访60个月,12个月总生存率分别为62%和28%(HR 0.30,95%CI 0.24-0.37)。
- axi-cel组客观缓解率76%(完全缓解率58%),CIT组客观缓解率28%(完全缓解率16%)。
- ≥65岁患者中,axi-cel较CIT的客观缓解率差异为57%(完全缓解率差异55%),有利于axi-cel。
- ECOG PS=2患者中亦观察到axi-cel较CIT在缓解率上获益幅度增加。
关键数值与推荐
- ≥65岁患者:axi-cel较CIT客观缓解率差异57%,完全缓解率差异55%。
- 总体匹配人群:axi-cel组12个月总生存率62% vs CIT组28%(HR 0.30,95%CI 0.24-0.37)。
- 总体匹配人群:axi-cel组客观缓解率76%(完全缓解率58%)vs CIT组28%(完全缓解率16%)。
临床怎么用
- 原文结论认为这些发现进一步支持在≥65岁及ECOG PS=2的复发/难治性大B细胞淋巴瘤患者中更广泛地使用阿基仑赛。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Axicabtagene ciloleucel (axi-cel) in trials has demonstrated favorable efficacy compared with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) large B cell lymphoma (LBCL). Herein, we compared the real-world effectiveness of axi-cel with efficacy and effectiveness of chemoimmunotherapy (CIT) in patients aged ≥65 years and patients with Eastern Cooperative Oncology Group performance status (ECOG PS) of 2. A total of 1146 patients treated with commercial axi-cel for R/R LBCL with ≥2 lines of prior therapy were included from the Center for International Blood and Marrow Transplantation Research prospective observational study, and 469 patients treated with CIT for R/R LBCL after ≥2 lines of prior therapy were included from SCHOLAR-1 (an international, multicohort, retrospective study). After propensity score matching, at a median follow-up of 24 months for patients receiving axi-cel and 60 months for patients receiving CIT, 12-month overall survival rates were 62% and 28%, respectively (hazard ratio, 0.30 [95% CI, 0.24-0.37]). Objective response rate (ORR) was 76% (complete response [CR] rate 58%) in patients receiving axi-cel versus 28% (CR rate 16%) for those receiving CIT. A 57% difference in ORR (55% difference in CR rate) favoring axi-cel over CIT was observed among patients aged ≥65 years. Increased magnitude of benefit in response rates for axi-cel versus CIT was also observed among patients with ECOG PS = 2. These findings further support the broader use of axi-cel in older patients and patients with ECOG PS = 2 with R/R LBCL.
引用
- Lunning MA, Wang HL, Hu ZH, et al. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024. PMID: 38504387. doi:10.1002/ajh.27283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。